Industry Focus
Healthcare: Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:21:49
- Mas informaciones
Informações:
Sinopsis
The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.
